Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -91.9% | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -265.4% | -20.8% | – | 91.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,363.7% | -100.6% | – | -389.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,434.2% | -111.4% | – | -313.3% |
| EPS Diluted | -0.056 | -0.034 | -0.05 | -0.042 |
| % Growth | -65.4% | 32.4% | -20.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |